LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Association between Psoriasis severity and steatosis measured by LIVERFASt
Association between Psoriasis severity and steatosis measured by LIVERFASt
LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy
Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy